Pace Life Sciences, LLC, a contract development, and manufacturing organization (CDMO), has acquired the Lebanon, New Jersey laboratory facility (formerly Whitehouse Analytical Laboratories) from Curia, a global contract research, development, and manufacturing (CDMO) company.
 
The site provides expertise and speed in development and commercial analytical laboratory services.
 
“This acquisition builds upon our leadership in the analytical services space to support emerging drug development partners through commercialization activities,” said Eric Roman, CEO of Pace. “I am excited to leverage this expansion with the New Jersey team to further collaborate with our pharma and biopharma clients.”
 
“Over the years, our Lebanon site has offered specialized analytical services that are highly valued by customers, and I am proud of the work that team has done,” said Philip Macnabb, CEO of Curia. “However, these services fall outside of our core capabilities, and we determined that this site would be better served under the leadership of an owner with overlapping interests, while allowing us focus on our specialties—discovery, development and manufacturing of life-changing medicine.”
 
The acquisition grows the Pace Life Sciences network to 9 sites able to support a wide spectrum of small and large molecule analytical services, formulation development, and early-stage drug product manufacturing services. The New Jersey location allows the company to expand its capacity for FDA-registered central laboratory services, including analytical chemistry, microbiology, container closure integrity testing (CCIT), sterility, and other packaging and delivery testing services.